Clinical use of raltegravir: a review

dc.creatorNunes, Estevão Portela
dc.creatorSantini-Oliveira, Marília
dc.creatorGrinsztejn, Beatriz
dc.date2018-11-22T14:28:14Z
dc.date2018-11-22T14:28:14Z
dc.date2010
dc.date.accessioned2023-09-26T23:02:18Z
dc.date.available2023-09-26T23:02:18Z
dc.identifierNUNES, E. P.; SANTINI-OLIVEIRA, M.; Grinsztejn, Beatriz Clinical use of raltegravir: a review. HIV Therapy, v. 4, n. 5, p. 531-542, 2010.
dc.identifier1758-4310
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/30154
dc.identifier10.2217/HIV.10.38
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8886116
dc.descriptionIn the last 5 years there have been important achievements in the field of HIV therapy with the availability of new classes of antiretrovirals together with a new generation of old classes. Among them, the development of raltegravir, the first commercially available component of integrase inhibitors, brought an extraordinary improvement in salvage therapy for HIV-infected patients, allowing for virologic suppression even in multi-experienced subjects, who until recently had limited treatment options. It was subsequently approved for initial treatment combined with a nucleoside/nucleotide backbone, and also became an interesting option for naive HIV-infected populations. Its unique characteristics, the limited potential for significant pharmacokinetic interactions with other drugs and excellent safety profile have increased interest in its use in different settings.
dc.description2025-08-30
dc.formatapplication/pdf
dc.languageeng
dc.rightsrestricted access
dc.subjectHIV
dc.subjectIntegrase inhibitor
dc.subjectRaltegravir
dc.titleClinical use of raltegravir: a review
dc.typeArticle


Este ítem pertenece a la siguiente institución